Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE + Nivolumab in Grade 3 NET/NEC
NCT04525638Phase 2Unknown
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jun 2020
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate, nivolumab in Neuroendocrine Neoplasm (NEN), neuroendocrine carcinoma (NEC), sponsored by Fundación de Investigación HM Hospitales. Status: unknown.
02
Drugs
lutetium Lu 177 dotatatenivolumab
03
Conditions
Neuroendocrine Neoplasm (NEN)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04525638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525638.